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SNP arrays provide reliable genotypes and can detect chromosomal aberrations at a high resolution. However, tissue heterogeneity is
currently a major limitation for somatic tissue analysis. We have developed SOMATICs, an original program for accurate analysis of het-
erogeneous tissue samples. Fifty-four samples (42 tumors and 12 normal tissues) were processed through Illumina Beadarrays and then
analyzed with SOMATICs. We demonstrate that tissue heterogeneity-related limitations not only can be overcome but can also be turned
into an advantage. First, admixture of normal cells with tumor can be used as an internal reference, thereby enabling highly sensitive
detection of somatic deletions without having corresponding normal tissue. Second, the presence of normal cells allows for discrimina-
tion of somatic from germline aberrations, and the proportion of cells in the tissue sample that are harboring the somatic events can be
assessed. Third, relatively early versus late somatic events can also be distinguished, assuming that late events occur only in subsets of
cancer cells. Finally, admixture by normal cells allows inference of germline genotypes from a cancer sample. All this information can be
obtained from any cancer sample containing a proportion of 40–75% of cancer cells. SOMATICs is a ready-to-use open-source program
that integrates all of these features into a simple format, comprehensively describing each chromosomal event.Introduction
SNP arrays simultaneously and reliably genotype hundreds
of thousands of single nucleotide polymorphisms (SNPs),
and they have moved genetic studies of tumor samples
into the high-throughput era (see Web Resources below).
SNP arrays are powerful for the identiﬁcation of chromo-
somal aberrations, especially deletions or ampliﬁcations.1
The power in tumor analysis results from the high SNP
density. Each SNP provides two valuable measures for
that purpose: the SNP signal intensity and the allelic im-
balance. The arrays produce signal intensitymeasurements
IA and IB, corresponding to the two SNP alleles A and B. The
SNP signal intensity is the sum of the signal of the two
alleles (IAþIB) and reﬂects the number of DNA copies.
The allelic-imbalance detection relies on SNPs that are het-
erozygous (AB) in the germline: some of them lose allele A
(genotype B0) or allele B (genotype A0) in the tumor,
which indicates loss of heterozygosity (LOH). LOH is qual-
itative, but the allelic imbalance can be made quantitative
by considering a ratio of IB/IA. This ratio provides precision,
such as in the case of duplication of one allele: a heterozy-
gous SNP can be identiﬁed with allelic ratios of either 1:2 or
2:1, depending on which allele is duplicated.
Interrogating multiple tumors with SNP arrays results in
large datasets that require computational assistance for
performance of the analyses on hundreds of thousands
of SNPs. Algorithms have been designed for either the Af-
fymetrix or Illumina platforms.2–8 These programs differThein their sensitivity for detecting alterations, requirements
for corresponding normal tissue samples, types of alter-
ations detected, interface with other programs, and acces-
sibility.9–28 In general, published studies show a relatively
low resolution compared to the potential of the arrays.9–28
One of the main limiting factors of SNP-array analysis in
tumors is tissue heterogeneity. Indeed, in a tumor, cancer
cells are admixed with normal cells, which dilute the
somatic cancer cell information.29 Equally importantly,
tumor stromal cells can contain both genomic and epige-
nomic alterations, often distinct from those in the epithe-
lial neoplasia.30–32 Microdissection can improve this is-
sue.16,17,21,25 However, absolute and complete separation
of the cancer cells from the normal or other ‘‘contaminat-
ing’’ cells is quite challenging. Several investigators
propose the use of immortalized cell lines, but other
problems could ensue, such as the induction of new ab-
normalities introduced by the culture methods or pro-
cess.10,11,22,26,29,33,34 Current algorithms for tumor analy-
sis either ignore or try to correct for the presence of
normal cells. In a recent publication, Yamamoto et al. pro-
posed a method with the signal arising from normal cells
as an element of the normalization process.8
In this report, we describe a set of methods, applied to
Illumina Beadarrays, that we developed to overcome tissue
heterogeneity and even turn it into an advantage. We
show how the normal cell contamination can be used as
an internal reference to yield highly sensitive detection
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helps indetermining theproportionof cells in a samplehar-
boring somatic deletions and ampliﬁcations and in ‘‘call-
ing’’ both germline and somatic (tumor) genotypes. This
method, which we called SOMATICs, compared favorably
with existing programs in terms of its sensitivity and speci-
ﬁcity when we applied in an original set of 54 samples.
Material and Methods
SNP Arrays and Tumor Samples
Fifty-four samples (42 tumors, 12 normal tissues) comprising gas-
trointestinal stromal tumors (GIST), paraganglioma, and pulmo-
nary chondroma tumors from 26 patients were used. All tumors
were examined histologically, and so percentage tumor and ad-
mixed normal cells are known by C.A.S. but kept blinded from
G.A. and C.E. Tumor samples were snap-frozen in liquid nitrogen
after surgery, then kept at 80C and pulverized under liquid ni-
trogen. Genomic DNA was extracted with QIAamp DNA micro
(QIAGEN, Valancia, CA) according to the manufacturer’s recom-
mendations. DNA was quantiﬁed with Nanodrop (Nanodrop
Technologies, Wilmington, DE), and the quality was veriﬁed by
agarose gel. SNP arrays were processed according to the manufac-
turer’s recommendations with the Inﬁnium II assay on Human-
Hap300 V2 arrays and run on the Illumina Beadstation (Genomics
Core Facility, Cleveland Clinic Foundation). This study has been
approved by the respective institutional review boards for the
protection of human subjects at the participating institutions.
Detection of Hemizygous Somatic Deletions
in Heterogeneous Tumor Samples
Somatic deletions are events occurring in cancer cells but not in
normal cells. When processing a cancer-tissue sample, the pres-
ence of some proportion of normal cells is hard to avoid. There-
fore, somatic deletions only occur in a subset of cells in a heteroge-
neous tumor sample, as compared to germline deletions that are
present in all the cells. In the case of hemizygous deletions (loss
of one allele), the presence of admixed normal cells without a de-
letion can impact the ability to detect somatic deletions by mask-
ing the true decrease in SNP intensity in the somatic cancer cells.
Similarly, the identiﬁcation of LOH in these heterogeneous tumor
samples is often compromised due to the masking of the hemizy-
gous (A0 or B0) SNPs in tumors by the heterozygous (AB) SNPs in
‘‘contaminating’’ normal cells.
The Illumina Beadstudio program provides a B-allele frequency
(BAF) measurement, which is able to address this latter situation.
BAF is a normalized metric that reﬂects the proportion of B-alleles
in each SNP, e.g., 0 for an AA SNP, 0.5 for an AB SNP, and 1 for a BB
SNP.Whenplotting the BAF ofmany consecutive SNPs in a normal
tissue, three distinct bands appear, corresponding to the three
genotypes: AA, AB, and BB (Figure S2, available online). BAF is
a quantitative measurement, reﬂecting allelic imbalance instead
of just LOH. In the case of a somatic deletion in a tissue sample,
the BAFmeasured is a combination of cancer cell BAF, representing
cancer-related deletion, and BAF from ‘‘contaminating’’ normal
cells that do not harbor the deletion. In this situation, BAF of
SNPs that are heterozygous in germline generate abnormal values
between 0 and 0.5 (deletion of allele B) or 0.5 and 1 (deletion of
allele A, Figure 1B). As a result, when plotting the BAF of many
consecutive SNPs belonging to a somatic deletion in a heteroge-
neous sample, the unique band of heterozygous SNPs is replaced904 The American Journal of Human Genetics 82, 903–915, April 2by a two-band pattern of SNPs that are heterozygous in germline
and hemizygous in tumor (Figures 1B–1E). These two-band pat-
terns actually reﬂect the allelic imbalance of the heterozygous
SNPs associated with the deletion of one allele.
SOMATICswas developed to automatically and accurately detect
somatic deletions on the basis of these speciﬁc two-band patterns.
The general ﬂowchart of SOMATICs is presented in Figure S1. The
following four steps are applied:
(1) Identification of Abnormal SNPs
Abnormal SNPs are deﬁned as those that are not normal AA, AB, or
BB. In terms of BAF, these SNPs have BAF values signiﬁcantly differ-
ent from the BAF of SNPs AA, AB, and BB. For each SNP chip,
SOMATICsdetermineswhat these normal values are by determining
referencedistributions foreachof the threegenotypes (seeAppendix).
With these distributions, a probability of being AA, AB, or BB can be
determined for each SNP, and abnormal SNPs are identiﬁed with dif-
ferent BAF threshold values, which are detailed in the Appendix.
(2) Identification of the Two-Band Patterns among the Abnormal SNPs
Two-band patterns are deviations from the unique central band of
normal heterozygous SNPs (BAF ¼ 0.5). The distance of deviation
can vary: the two bands can be obvious (Figure 1B), very close to
thebandsofhomozygousSNPs (Figure1C),orveryclose toeachother
(Figure 1E). SOMATICs uses three different methods to identify these
SNP patterns in each of these situations (for details, see Appendices).
(3) Determination of Boundaries for each Two-Band Pattern
This step converts individual SNPs into chromosomal regions. The
smoothing process (Adaptative Weights Smoothing35) identiﬁes
all the consecutive SNPs that should be considered as having a
constant BAF (for details, see Appendices).
(4) Calling Deletions in the Smoothed Fragments
For each SNP, Illumina Beadstudio generates the logR ratio metric,
which reﬂects the number of DNA copies. The logR ratio is a log-
transformed ratio of the measured SNP signal intensity by the ex-
pected intensity if two copies of DNA are present. This logR ratio is
normalized so that two copies of DNA generate a logR ratio z0,
whereas one copy of DNA generates a logR ratio z0.5. Use of
the logR ratio to call a deletion might seem the most straightfor-
ward. However, the logR ratio is less responsive than the BAF,29
and in the case of somatic hemizygous deletions, this difference
is even more important (see Results and Discussion section). For
this reason, instead of just considering the logR ratio, SOMATICs
uses the BAF to detect all potential deletions and subsequently
uses the logR ratio to conﬁrm the deletion.
To call a region ‘‘deleted,’’ the following three criteriamust bemet:
i. There must be a signiﬁcant decrease of the logR ratio.
ii. There must be a shift of the logR ratio that is concordant
with the proportion of cells harboring the deletion. For in-
stance, for a deletion occurring in almost all the cells in
a sample, the logR ratio is expected to be close to 0.5,
whereas for a deletion occurring in very few cells, the
logR ratio is expected to be close to 0.
iii. The boundaries of the two-band pattern and the region
with decreased logR should be concordant (for details, see
Appendices).
Detection of Other Chromosomal Aberrations
in Heterogeneous Tumor Tissue Samples
Germline Deletions
Unlike somatic deletions, germline deletions of one allele are chro-
mosomal aberrations occurring in all the cells of an individual.008
Figure 1. Automatic Detection of Chromosomal Aberrations in Heterogeneous Tissue Samples
In each panel, the BAF and the logR ratio are plotted along chromosomal regions. The black boxes at the bottom represent detection with
SOMATICs and other currently available methods, namely, Beadstudio LOH score (y axis range from 0 to 5), dChip (default detection
threshold), and CNVPartition.
(A) Small germline deletion is revealed as a decreased logR ratio (0.5), and the band of heterozygous SNPs centered on 0.5 is absent on
the BAF plot.
(B–E) Various types of somatic deletions revealed on the BAF plot in which the single band of heterozygous SNPs is replaced by two bands
and the logR ratio is decreased, but to a lesser extent as compared to germline deletions. The various types of somatic deletions are man-
ifested by differences in the position and the size of the two-band patterns. Note that (E) shows a somatic deletion occurring in very few
cells. In this situation, detection is easier with use of the BAF (two-band pattern) than with the logR (reduced shift downward). However,
the copy number call as a ‘‘deletion’’ relies on a significant decrease of the logR (in this situation, p < 2.2e16).
(F) Wavy fluctuations of logR ratio, which is not reflected in the BAF, are artefacts. This artifact is responsible for false-positive detection
by programs focusing only on logR ratio.
(G) Two small germline duplications are revealed on the BAF plot as heterozygous SNPs showing a two-band pattern with a logR ratio that
is increased.
(H) In somatic duplication, the two bands are closer to one another and the increase in logR is less than that of germline amplification
(G). As with (E), for (H), the BAF two-band pattern is easier to detect than is the logR shift upward. However, the copy number call as an
‘‘amplification’’ relies on a significant increase of the logR (in this case, p < 2.2e16). SOMATICs can detect and differentiate the various
types of alterations when other programs cannot.Therefore, hemizygous germline deletions can be detected in het-
erogeneous tumor samples via hemizygosity, whereby hemizy-
gous regions generate homozygous SNP genotype calls and de-
creased signal intensity. SOMATICs identiﬁes a germline deletion
as any consecutive stretch ofR 5 SNPs, identiﬁed with BAF values
of 0 (A0) or 1 (B0), which also have a decreased logR intensity. The
logR decrease is ascertained as described previously with the three
criteria detailed in (4) (‘‘Calling Deletions in the Smoothed Frag-
ments’’):When these criteria are not met, long stretches of homo-
zygous SNPs can reveal uniparental disomy. The discrimination
between uniparental-disomy-related stretches and randomlyTheoccurring stretches of homozygous SNPs can be performed with
existing programs such as dChip.5 When two alleles are deleted
(homozygous deletions), the logR of SNPs dramatically drops to
very low values (<1); SOMATICs calls two or more consecutive
SNPs with such logR values as homozygous deletions. See
Figure 1A.
Somatic and Germline Amplifications
Similar to somatic deletions, ampliﬁcations of one allele result in
allelic imbalance of heterozygous SNPs, which can be detected
by BAF two-band patterns, as described previously. This occurs
in both germline (Figure 1G) and somatic ampliﬁcationsAmerican Journal of Human Genetics 82, 903–915, April 2008 905
(Figure 1H), and thus, SOMATICs can detect both with the same
strategy as that for somatic deletions (except that the logR ratio
is now increased): when two bands are close to each other in the
BAF two-band pattern and the logR ratio shift is decreased
(Figure 1H), a somatic ampliﬁcation is detected.
Proportion of Cells Harboring Somatic Deletions and
Ampliﬁcations in Heterogeneous Tissue Samples
In heterogeneous tissue samples, the allelic imbalance related to
somatic deletions and ampliﬁcations of one allele can be identiﬁed
by the BAF two-band patterns described previously. The position
of the two bands is determined by the relative proportions of cells
harboring a given somatic event versus cells without this event.10
For example, in the case of a somatic deletion, the two bands are
close to the bands of homozygous SNPs when the tissue contains
a majority of cells harboring the deletion (Figure 1C). In contrast,
when the tissue contains very few cells harboring the deletion, the
two bands are close to each other in the center of the BAF plot
(Figure 1E). On the basis of this feature, SOMATICs provides an as-
sessment of the proportion of cells, ‘‘c,’’ harboring a somatic event.
We introduce c in the three most common somatic events: hemi-
zygous deletions, duplication of one allele, and deletion of one
allele with duplication of the other. For each situation, the exact
relationship between c and the allelic ratio IB/IA can be speciﬁed
as follows:
Somatic deletion of allele B:
IB=IA ¼ 1 c [Equation 1]
Somatic duplication of allele A:
IB=IA ¼ 1=ð1þ cÞ [Equation 2]
Somatic deletion of allele B and duplication of allele A:
IB=IA ¼ ð1 cÞ=ð1þ cÞ [Equation 3]
In addition, Illumina deﬁnes BAF as:10
tanðBAFÞ ¼ IB=IA [Equation 4]
Combining equations 1, 2, and 3 with equation 4, we can explic-
itly solve for c as a function of BAF:
Somatic deletion of allele B:
c ¼ 1 tanðBAFdel3p=2Þ [Equation 5]
Somatic duplication of allele A:
c ¼ 1=tanBAFampl3p=2
 1 [Equation 6]
Somatic deletion of allele B and duplication of allele A:
c ¼ 1 tanBAFdeldupl3p=2

=

1þ tanBAFdeldupl3p=2

[Equation 7]
Among these three formulae, the appropriate one is chosen
according to the logR ratio. In addition, these formulae require
only one BAF value, yet there are two BAF values for each two-
band pattern. Therefore, the two bands are transformed into a sin-
gle band by ‘‘folding’’ the BAF plot so that the upper band is super-
imposed onto the lower band (Figure 2A). Themedian value of the
SNPs in the unique band is used for computing c(for details, see
Appendices).
Germline Genotype Inference from Cancer Samples
In normal tissues, BAF plots show three clearly distinct bands of
SNPs, each corresponding to one genotype (AA, AB, or BB). In can-906 The American Journal of Human Genetics 82, 903–915, April 20cer samples, the majority of chromosomal regions do not harbor
any aberrations. In this case, genotype inference is clearly discern-
able with the use of ﬁxed BAF thresholds (Figure 3A). In chromo-
somal regions with somatic deletions or ampliﬁcations, the
unique band of heterozygous SNPs is replaced by two bands:
they correspond to SNPs that are heterozygous in the germline.
SOMATICs systematically looks for these two-band patterns: the
SNPs that belong to the two bands are called heterozygous in
germline. This genotyping is highly reliable as far as these two
bands can be discriminated from the homozygous SNPs. This is
true for the vastmajority of chromosomal aberrations in amajority
of cancer samples. However, in the speciﬁc case of a hemizygous
deletion occurring in almost all the cells of a sample, the two
bands are difﬁcult to discriminate from the homozygous SNP
bands (Figure 1C). In this case, SOMATICs uses a strategy of best
discrimination to warrant the accuracy of the genotype (for
details, see Appendices).
Third Party Softwares
All original scripts were written in R, version 2.4.36 All the scripts
are available as supplemental data. Speciﬁc R packages dip test
and Adaptive Weights Smoothing (aws) were included in
SOMATICs.37,38 BeadStudio 3.1 was used to generate the BAF and
logR ratios, which were exported as text ﬁles. The LOH score,
Chromozone, and CNVPartition plug-ins provided with this ver-
sion of BeadStudio were used to identify LOH, allelic imbalance,
and CNV. dChip7 (release Dec 7, 2006) was applied to the normal-
ized allele intensities X and Y obtained from Illumina BeadStudio
3.1, along with the genotype calls, as recommended. The SNP an-
notations were also included (physical positions provided by Illu-
mina). The LOH analysis was performed with Hidden Markov
Models for unpaired data, assuming a proportion of heterozygous
SNPs of 35% for the Illumina HumanHap300 (determined from
the normal samples). All other parameters were set to default
values.
Results
Accurate Detection of Deletions and Ampliﬁcations
in Heterogeneous Tissue Samples with SOMATICs
SOMATICs automatically detects the deletions and ampliﬁ-
cations in a tissue sample processed on Illumina Beadar-
rays. The originality of the approach is that it can speciﬁ-
cally interpret the somatic events occurring in a subset of
cells within a sample, typically in the cancer cells of a het-
erogeneous tissue sample ‘‘contaminated’’ by normal cells.
In the case of one allele’s somatic deletions in particular,
the presence of normal cells is responsible for speciﬁc
two-band patterns of allelic imbalance with the Illumina
BAF measurement. Similar two-band patterns are associ-
ated with the ampliﬁcation of one allele, another case of al-
lelic imbalance. SOMATICs automatically detects these
two-band patterns (Figure 1), even when somatic deletions
or ampliﬁcations occur in a small proportion of the cells
(Figures 1E and 1H) or when the somatic events are phys-
ically small (Figures 1D and 1G).
Compared to other algorithms, SOMATICs deals better
with tissue heterogeneity. For example, methods of look-
ing for deletions based on LOH detection (dCHIP5 and08
Figure 2. Proportion of Cells, ‘‘c,’’ in a Heterogeneous Tumor Sample Harboring a Somatic Genetic Event
(A) BAF and the logR ratio plots from one chromosome reveal three somatic hemizygous deletions occurring in three different proportions
of cells. The BAFdel of heterozygote SNPs is measured after ‘‘folding’’ the BAF plot along an axis centered around 0.5. Then BAFdel is used to
determine c with the formula designed for somatic deletions (see Appendices for details).
(B) Frequency distribution showing the number of SNPs included in the somatic deletions by the proportion of cells, ‘‘c,’’ in which these
events occur. Some somatic deletions occur in over 80% of cells (rightmost bar). Assuming that only cancer cells harbor somatic
deletions, the proportion of cancer cells is then estimated as 80% in this sample.
(C) Schematic illustrating the relationship between the chronology of somatic events during tumorigenesis and the proportion of cancer
cells with these events. Early somatic events are present in all (or a great majority of) cancer cells, whereas late somatic events are only
present in subsets of cells.LOH score, Illumina Beadstudio) detect only somatic de-
letions occurring in almost all the cells of the sample
(Figure 1C). These methods cannot detect deletions occur-
ring in lower proportions of cells (Figures 1B and 1E), germ-
line ampliﬁcations (Figure 1G), or somatic ampliﬁcations
(Figure 1H). In addition, LOH-detection approaches can-
not reveal small chromosomal events (Figure 1D). Like
SOMATICs, Chromozone (Illumina Beadstudio) detects
the BAF two-band patterns indicating allelic imbalance.
However, the sensitivity of Chromozone is limited: small
deletions (Figure 1D) or deletions occurring in very few
cells (Figure 1E) are not detected. In addition, Chromozone
provides only graphic bookmarks, without tabular output
or boundary deﬁnitions. CNVPartition (Illumina) is solely
based on the logR ratio. However, in the case of somatic
events, normal cell contamination dilutes the logR ratio,
decreasing its sensitivity (Figures 1B–1H). Note that the
human eye can barely perceive the difference between
plots in Figure 1E (downward for deletion) and Figure 1H
(upward for ampliﬁcation). However, SOMATICs detects
this shift of logR upwards (ampliﬁcation) or downwards
(deletion) with a p < 2.2e16. In addition, CNVPartitionThegenerates false positives in noisy samples, unlike SOMATICs
(Figure 1F).
With SOMATICs, germline deletions can be distin-
guished from somatic deletions, even when the latter
occur in almost all the cells of a tissue sample. This discrim-
ination is based on the identiﬁcation of the speciﬁc BAF
two-band pattern that is associated with somatic deletions
but not with germline deletions. Figure S3 shows two re-
gions of the same size and SNP density, one with a somatic
deletion occurring in almost all of the cells (two-band pat-
tern very close to the homozygous SNPs), the other with
a germline deletion (without the two-band pattern).
SOMATICs discriminates between these two situations.
Unique integrated outputs are also generated by SO-
MATICs. All relevant information associated with each
chromosomal aberration is gathered, namely the bound-
aries, the aberration type (deletion, ampliﬁcation, deletion
and/or duplication), the affected compartment (germline
or somatic), the proportion of cells in the sample that har-
bor the aberration (see next paragraph), and the criteria
reﬂecting the reliability of the ﬁnding (signiﬁcance of
statistical tests and size of the fragment).American Journal of Human Genetics 82, 903–915, April 2008 907
Figure 3. Germline Genotype Inference
from a Heterogeneous Cancer Sample
(A) Schematic representation of the calling
methods used by SOMATICs and by Bead-
Studio. SOMATICs is specifically designed
to generate appropriate calls in genomic
regions with allelic imbalance. When bands
of heterozygous AB SNPs can be discrimi-
nated from the bands of homozygous AA
and BB SNPs, a reliable germline genotype
call can be provided.
(B) illustrates enotyping call rates in re-
gions of allelic imbalance with SOMATICs
and BeadStudio, and (C) illlustrates geno-
typing accuracy in regions of allelic imbal-
ance with SOMATICs and BeadStudio. These
results were obtained by comparison of ge-
notypes inferred from tumors with geno-
types read in normal corresponding tissue
obtained with seven pairs of matched
samples. The results in (B) and (C) are ex-
pressed as a function of the distance from
the heterozygote bands to the homozygote
bands, on a scale of 0 to 0.5, representing
the mean BAF of the lower band of hetero-
zygote SNPs. This mean BAF is converted
into a proportion of cells, ‘‘c,’’ with allelic
imbalance by use of the formula for so-
matic deletions (see Appendices for de-
tails).Proportion of Cells with a Somatic Event
In heterogeneous tissue samples, somatic deletions and
ampliﬁcations occur only in a subset of cells. SOMATICs
is able to determine the proportion of cells, ‘‘c,’’ in the sam-
ple that harbor the somatic event (Figure 2B). For validat-
ing the whole procedure for estimating c, data from a serial
dilution of cancer cells with normal matched cells gener-
ated by Pfeiffer et al.10 were used. These experiments
included SNP-array runs for each dilution of cancer cell
proportions of 0, 25, 50, 75, and 100%. A complex set of
consecutive chromosome aberrations that included a large
deletion of one allele harbored by all of the cancer cells
(13q distal) was shown by the investigators. In the chro-
mosomal region with the deletion, the median BAFs of
the lower band on the two-band patterns were at approxi-
mately 0.5, 0.45, 0.35, 0.15, and 0 for the different dilu-
tions. Using these rough values with our ‘‘deletion’’
formula within SOMATICs, we ﬁnd that the estimated pro-
portion of cancer cells, ‘‘c,’’ are 0, 15, 39, 76, and 100%,
which are close to the actual dilutions at 0, 25, 50, 75,
and 100%.
Determination of the Tumor Content
When the proportions of cells determined for all the so-
matic deletions in a sample are gathered, a distribution
of these values can be generated. Figure 2B shows an exam-
ple with two peaks in the distribution. The highest peak is908 The American Journal of Human Genetics 82, 903–915, April 20centered at 80%. That means that some somatic deletions
occurred in up to 80% of the cells of the sample. If we as-
sume that only cancer cells, not normal cells, harbor dele-
tions, then 80% of the cells in the sample are cancer cells.
Tumor content is difﬁcult to measure, even with anatomo-
pathological approaches. To our knowledge, this is the ﬁrst
computational method that determines the tumor con-
tent.
A ﬁrst application of the proportion of cancer cells is
obvious: when the tumor content is very low, one would
expect a high false negative rate for identifying somatic
events. Therefore, the sensitivity of an SNP-array experi-
ment to detect somatic events can now be assessed.
Germline Genotype Inference
SOMATICs is uniquely able to infer the germline genotype
from a cancer sample, even in regions with allelic imbal-
ance (Figure 3). To assess the reliability of the germline calls
made by SOMATICs, we compared the germline calls in-
ferred from 17 tumors with the genotype calls generated
from their normal corresponding tissue. With the use of
SOMATICs in the cancer samples, 99.6% of the genotypes
were called, and among them, the genotyping accuracy
was 99.75%.
To assess the impact of allelic imbalance on the germline
genotyping, we measured the genotyping call rates and ac-
curacy speciﬁcally in chromosomal regions with somatic08
deletions or ampliﬁcations. When the bands of the two-
band patterns are distinct from the homozygous SNPs on
the BAF plot, call rates remain high and genotyping errors
are low (Figure 3A). When the BAF of the lower band in
a two-band pattern isR0.2, the call rate is 99.9% and the-
genotyping accuracy is higher than 99.6%. This limit cor-
responds to a somatic deletion occurring in z70% of the
cells in a sample (Figure 3B and 3C). When the bands
come closer to the bands of homozygous SNPs (e.g., BAF
of the lower band between 0.1 and 0.2 [representing a so-
matic deletion in 84% of the cells in a sample]), the call
rate remains at 98.8%, with a genotyping accuracy decreas-
ing to 97.6%. For comparison, in this situation, BeadStudio
germline genotyping is associated with a low call rate
(74.5%) and low genotyping accuracy (91.5%). When the
bands come even closer (BAF of the lower band < 0.1),
discrimination between germline heterozygous and ho-
mozygous SNPs become challenging. In this situation,
SOMATICs achieves a call rate of 80.5%, at an accuracy of
95.5%. For comparison, the call rates from BeadStudio
are high (95.6%), but, importantly, this is due to the incor-
rect calling of germline heterozygous SNPs as homozygous,
therefore providing an accuracy of 73.6%.
Discussion
Up until now, SNP-based analysis for somatic deletion or
ampliﬁcation required paired germline and tumor samples.
Furthermore, cellular heterogeneity in tumors, usually nor-
mal and tumor cellular admixture, has proven problematic
for such SNP-based studies. SOMATICs was designed for
use in heterogeneous tissue studies, such as those utilizing
tumor tissue samples. We can also imagine that such a
technique might be amenable to examination for genetic
alterations that occur in a germline mosaic manner. The
main innovation of SOMATICs is the utilization of normal
cell admixture as an advantage rather than a liability.
SOMATICs enables the automatic detection of deletions
and ampliﬁcations from Illumina Beadarrays, a feature
already proposed by other methods.5,7,29 However, com-
pared to these other available methods, SOMATICs appears
to be quite sensitive, even when other methods fail to
detect very small deletions or ampliﬁcation. Both allelic
imbalance and DNA copy-number alterations related to
deletions and ampliﬁcations are integrated into a single
analysis in SOMATICs, and the background ‘‘noise’’ from
each SNP array is taken into account. An added advantage
of the program’s design is that the program code is open
and modular, permitting one to perform custom modiﬁ-
cations; e.g., to run a speciﬁc analysis or to generate spe-
ciﬁc output formats.
Two original features are implemented in SOMATICs: the
proportion of cells harboring a somatic event and the
germline genotype inference from a cancer sample. One
extrapolated utility for the ability to determine the propor-
tion of a somatic genetic event is the ability to quickly pre-Thedict relatively early and late somatic events. Because of ac-
cumulated work over the last two decades, it is generally
accepted that relatively early somatic events have a higher
frequency of cells harboring those events, as compared to
later somatic events in which there would be a lower fre-
quency. For example, Figure 2C is a schematic representa-
tion of the genetic accumulation of the somatic chromo-
somal aberrations throughout the clonal growth of the
tumor. At the end, the proportion of cancer cells with a so-
matic event reﬂects the chronology of the event: early
somatic events are present in a majority of cancer cells,
whereas late somatic events are present only in a small sub-
set of cancer cells. Going back to the distribution of propor-
tions of cells harboring somatic events in Figure 2B, if we
assume that 80% of the cells are cancer cells, then the
events occurring in 80% of the sample cells (i.e., in the ma-
jority of the cancer cells) can be qualiﬁed as relatively ear-
lier somatic events, whereas those occurring in 35% of the
sample cells (i.e., in less than half of the cancer cells) can be
qualiﬁed as relatively later somatic events. Finally, the abil-
ity to infer germline genotype from only tumor samples
without the physical existence of corresponding germline
samples makes this a useful method, because correspond-
ing germline tissue might not always be attainable.
SOMATICs is able to achieve an accuracy of > 95% in this
regard, compared to < 75% for Beadstudio. This is corrob-
orated by a completely independently performed study39
to look for germline deletions in four selected candidate
genes—SDHB, SDHC, SDHD and PDGRFA—in a proportion
of samples that were common to this study. When the re-
sults were compared, the germline deletions identiﬁed by
the experimental candidate-gene germline-deletion-analy-
sis study (e.g., see Figure 7 of Pasini et al.39) were noted as
germline-deletion calls by SOMATICs.
Appendix A. Detection of Somatic Deletions
in Heterogeneous Tumor Samples
The detection of somatic deletions is performed by these
four steps (Figure S1):
I. Identiﬁcation of Abnormal SNPs that are neither
Entirely Homozygous nor Entirely Heterozygous
on the basis of BAF
To ascertain that a SNP is neither a ‘‘normal’’ homozygous
SNP nor a ‘‘normal’’ heterozygous SNP on the basis of its
BAF, one needs to ﬁrst determine the BAF values of homo-
zygous and heterozygous SNPs that are ‘‘normal,’’ e.g., not
belonging to any ampliﬁcation or deletion event. Distribu-
tions of normal values are determined separately for each
array, because these distributions will reﬂect the experi-
mental variability from array to array. Toward this end,
SOMATICs looks for ‘‘normal’’ chromosomes for each sam-
ple. Such chromosomes can be identiﬁed as having three
thin bands on the BAF plot (Figure S2), each corresponding
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temporary assignment of SNPs to one of the three geno-
types is performed with BAF thresholds of 0.25 and 0.75
(Figure S2). Assuming that there is always at least one nor-
mal chromosome in any sample, this chromosome is se-
lected as the one with the lowest BAF variance for each
of the three genotypes. The BAF values for the SNPs from
this chromosome are used as reference distributions for
each of the three genotypes.
These reference distributions are used to deﬁne three
BAF regions, termed ‘‘blue,’’ ‘‘green,’’ and ‘‘red,’’ displayed
in Figure S2. A separate algorithm is used for each of these
regions to identify abnormal SNPs and their organization
into two-band patterns:
1. In the blue regions, abnormal SNPs are close but dis-
tinct fromhomozygous SNPs. The BAF values of these
abnormal SNPs are deﬁned to be between 0.25 and the
95th percentile of the AA reference distribution, or be-
tween 0.75 and the 95th percentile of the BB reference
distribution.
2. In the green regions, abnormal SNPs are obviously
abnormal, given that they are distinct from the ref-
erence AA, AB, and BB regions. The BAF values of
these abnormal SNPs are deﬁned to be between the
99.9th percentile of the AA reference distribution
and the 99.9th percentile of the BB reference distri-
bution.
3. In the red region, abnormal SNPs have BAF values
close to 0.5. This region is deﬁned to be between
0.25 and 0.75.
II. Identiﬁcation of BAF Two-Band Signature of Allelic
Imbalance among the Abnormal SNPs
Three speciﬁc algorithms are applied to detect the BAF two-
band patterns of allelic imbalance among the abnormal
SNPs:
1. In the green regions, the two-band patterns are obvi-
ous and distant from the homozygous SNP bands
(Figure 1B and Figure S2B). In this case, the two-
band patterns are deﬁned as any succession of R
three SNPs in the green region. These SNPs can be
consecutive, or they can be separated by homozy-
gous SNPs, given that hemizygous SNPs are called
‘‘homozygous’’ with the BAF.
2. In the blue regions, the two-band patterns display
bands of SNPs close to the homozygous SNPs (Fig-
ure 1C and Figure S2). In this case, the two-band pat-
terns are identiﬁed with a likelihood ratio, which
divides the likelihood that the abnormal SNPs are
heterozygous in the germline by the likelihood that
the abnormal SNPs are homozygous. The likelihood
that the abnormal SNPs are heterozygous in the
germline is estimated by the concordance of the rel-
ative proportion of heterozygous and homozygous
SNPs with the expected 1/3 proportion of heterozy-910 The American Journal of Human Genetics 82, 903–915, April 200gous SNPs observed for the entire SNP array, by use
of a Chi-square test (or a Fisher’s exact test when
there are less than ﬁve heterozygous or homozygous
SNPs or less than 20 SNPs). The likelihood that the
abnormal SNPs are homozygous is computed as the
product of the probabilities that each abnormal SNP
is actually a homozygote. These probabilities are de-
termined with the probability-distribution function
of the reference AA and BB distributions [see section
i above]. Any succession of R ﬁve abnormal SNPs
with BAFs close to 0 or 1, e.g., belonging to the
blue regions, [see section i above] is tested. With
this approach, subchromosomal regions with long
stretches of homozygous SNPs generate likelihood
ratios lower than 20, and subchromosomal regions
with bands of heterozygous SNPs overlapping with
the homozygous SNPs generate likelihood ratios
over 100 (Figure S3). A decision threshold of 40 was
chosen.
3. In the red regions, the two-band pattern displays two
bands close to each other (Figures 1E and 1H, Fig-
ure S2). In this case, the two-band patterns are de-
ﬁned as regions with a bimodal BAF distribution of
heterozygous SNPs, in contrast to normal heterozy-
gous SNPs that show a unimodal distribution. The
mode of the distribution is identiﬁed by application
of the Hartigan’s dip test for unimodality40 to all of
the heterozygous SNPs with BAFs between 0.25 and
0.75. Moving windows of three widths are used
(1000, 200, and 50 SNPs), with steps of 1/25th the
width. In each window, a dip score is generated.
The dip score is a nonparametric statistic that mea-
sures deviation from unimodality. A null distribution
for the dip score is generated via random sampling
for each window size and for each sample. For in-
stance, for the 200 SNP window, 1000 dip scores
are calculated from 200 BAFs randomly sampled
from the reference heterozygous SNPs, generating
the distribution of dip scores for heterozygous SNPs
without allelic imbalance. The 99th percentile of this
distribution is used as a threshold for calling allelic
imbalance. All SNPs located inside a positive window
5 1/2 step are preliminarily considered to be in alle-
lic imbalance. This strategy is very sensitive, but it
might generate false-positive calls, especially for nor-
mal SNPs that are near a cluster of SNPs with an ob-
vious bimodal distribution. In this situation, how-
ever, because the bimodal portion of the window is
obvious, the segmentation procedure (see section
III below) will identify the different segments. Fi-
nally, the BAFs of heterozygous SNPs in each seg-
ment are compared to the reference BAF distribution
for heterozygote SNPs by use of either a Student t
test (if N > 20) or a Wilcoxon test (N % 20). Only
segments that reach signiﬁcance (two-sided
p values< 0.05) in this test are deemed to be in allelic
imbalance.8
III. Determination of Boundaries for Each Two-Band
Allelic Imbalance Pattern
In order to convert successions of SNPs into chromosomal
regions and determine the boundaries of each region in al-
lelic imbalance, the Adaptative Weights Smoothing (AWS)
procedure36 (as implemented in the AWS R package) is
applied as follows:
SNPs belonging to the two-band patterns are selected as
the SNPs having BAF values between the 99th percentile of
the reference distribution of AA SNPs and the 99th percen-
tile of the reference distribution of homozygous BB SNPs.
The two bands are converted into a single band by ‘‘fold-
ing’’ the BAF plot so that the two bands are superimposed
(Figure 2A). The ‘‘folding’’ is centered on the mean BAF of
reference heterozygous SNPs (instead of 0.5). Indeed, careful
analyis with the reference heterozygous SNPs reveals that
the mean BAF (denoted BAFmhet) of normal heterozygous
SNPs is actually lower than 0.5, with a speciﬁc value
for each experiment. For the ‘‘folding,’’ any SNP with
a BAF higher than BAFmhet was converted to ﬁt into the
[0, BAFmhet] interval, by use of the following transforma-
tion:
BAFconverted ¼ BAFmhet  ðBAF BAFmhetÞ
3BAFmhet=ð1 BAFmhetÞ ½Equation 1
These SNPs are submitted into the ASWH function. The
ASWH function is used with the following parameters: hi-
nit ¼ 3, hmax ¼ 500, p ¼ 0, sigma2 ¼ 0.01. This procedure
generates a ‘‘smoothed’’ value for each SNP. Consecutive
SNPs with smoothed values that differ by less than 0.02
units are deemed to be part of the same segment.
IV. Testing for DNA Copy-Number Variation within
the Two-Band Pattern of Allelic Imbalance
For each chromosomal segment in allelic imbalance iden-
tiﬁed as described above, the logR ratio is explored. The
following three criteria have to be met to call a deletion:
1. There must be a signiﬁcant decrease of the logR ratio:
the mean logR ratio of the SNPs within that region is
compared to a reference logR ratio distribution. This
reference distribution is obtained from distribution
of logR arising from a normal chromosome in the
sample, deﬁned as the one with the smallest logR
variance and no aberrations as ascertained by
a unique band of heterozygous SNPs on the BAF
plot. The distribution is centered at 0 by subtracting
its mean. The comparison between the SNPs from
the region in allelic imbalance and the reference
logR distribution is performed by use of either the
Student t test (more than 20 SNPs) or the nonpara-
metric Wilcoxon rank sum test (less than 20 SNPs).
Signiﬁcance is called for two-sided p values < 0.05.
2. The decrease of the logR ratio must be concordant
with the proportion of cells, ‘‘c’’ harboring the
somatic event. The median logR ratio of SNPs withinThethe region in allelic imbalance must be less than
[0.3 3 c].
3. The boundaries of the region in allelic imbalance and
of the region with decreased logR ratio should be
concordant. For this criterion, SOMATICs screens
the boundaries of the two-band patterns for a shift
in the logR ratio. The criterion is met when the me-
dian logR ratio of the ﬁve SNPs outside each bound-
ary is at least [0.3 3 c] units higher than the median
logR ratio of the SNPs within the boundaries.
Appendix B. Proportion of Cells Harboring
Somatic Deletions and Amplifications in
Heterogeneous Tissue Samples
BAF is a normalized measurement of the B/A allelic ratio.
The non-normalized measurement is denoted ‘‘q’’ in the
original Illumina Beadstudio paper, with:
Theta ¼ ð2=pÞ3 arctanðIB=IAÞ [Equation 2]
where IA and IB are the normalized intensities of A and B.
Theta is normalized into BAF by linear interpolation with
‘‘canonical’’ theta values obtained from a panel of normal
individuals so that BAF values are approximately 0, 0.5,
and 1 for SNPs with genotypes AA, AB, and BB, respec-
tively. As a result, we have:
IB=IA ¼ tanðBAF3p=2Þ [Equation 3]
with IB/IA¼ 0 for BAF¼ 0 (genotype AA, B allele signal¼ 0),
IB/IA ¼ þN for BAF ¼ 1 (genotype BB, A allele signal ¼ 0),
and IB/IA ¼ 1 for BAF ¼ 0.5 (genotype AB, A allele signal ¼
B allele signal).
We let ‘‘c’’ denote the proportion of cells in the sample
harboring a somatic event. In the case of a somatic hemi-
zygous deletion of allele B, the signal from allele B arises
only from the normal cells present in the sample, which
are in proportion (1  c). Therefore the signal from allele
A is decreased by a factor of (1  c), and the IB/IA ratio is in-
creased by a factor of (1 c). For heterozygous SNPs, IB/IA is
equal to 1. Using Equation 3, we then obtain:
1 c ¼ tanðBAFdel3p=2Þ [Equation 4]
which can be converted into
c ¼ 1 tanðBAFdel3p=2Þ: [Equation 5]
In the case of a somatic ampliﬁcation via duplication of
allele A, the signal from allele A is doubled in the cancer
cells, which are in proportion c, and unchanged in the
normal cells, which are in proportion (1  c). Therefore,
the signal from allele A is increased by a factor of [2 3 c þ
(1  c) ¼ (1 þ c)]. Therefore, the B/A ratio is decreased by
a factor of (1 þ c). For heterozygous SNPs, IB/IA is equal
to 1. Using Equation 3, we obtain:
1=ð1þ cÞ ¼ tanBAFampl3p=2

[Equation 6]
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c ¼ 1=tanBAFampl3p=2
 1 [Equation 7]
In the case of a somatic deletion of allele B with duplica-
tionof alleleA, the signal fromalleleA is doubled in the can-
cer cells, which are in proportion c and unchanged in the
normal cells, which are in proportion (1  c). Therefore,
the signal from allele A is increased by a factor of [2 3 c þ
(1  c) ¼ (1 þ c)]. The signal from allele B arises only from
thenormal cells present in the sample, which are in propor-
tion (1  c). Therefore, the signal from allele B is decreased
by a factor of (1  c). As a consequence, the B/A ratio is in-
creased by a factor of [(1  c)/(1 þ c)]. For heterozygote
SNPs, IB/IA is equal to 1. Using Equation 3, we obtain:
ð1 cÞ=ð1þ cÞ ¼ tanBAFdeldupl3p=2

[Equation 8]
so that
c ¼ 1 tanBAFdeldupl3p=2

1þ tanBAFdeldupl3p=2

[Equation 9]
In order to determine which of the above three formulae
should be used to compute c, SOMATICS assigns an a priori
alteration type to each region in allelic imbalance, by use
of the logR ratio intensity measurement. The mean logR
ratio in that region is compared to a reference logR (see
SOMATICs Code, Web Resources below). Regions with a
signiﬁcantly lower logR are assigned as deletions, those
signiﬁcantly higher as ampliﬁcations, and those not signif-
icantly different (at the 0.05 level) as deletion/duplication
(also known as copy-neutral LOH or neutral allelic imbal-
ance). On the basis of these a priori alteration-type assign-
ments, the appropriate formula is used to determine c.
Because signiﬁcant variations of logR ratio can be noise-
related artefacts, an a posteriori conﬁrmation of the pre-
liminary assignment is performed with c (see section iv
of Appendix A). Any assignment of a deletion or an ampli-
ﬁcation that cannot be conﬁrmed is considered as a dele-
tion/duplication, and c is recomputed accordingly.
For any of these three somatic events, the band of het-
erozygous SNPs on the BAF scatter plot is split into two
bands (Figure 1), one with an average BAF lower than 0.5
and the other with an average BAF higher than 0.5. The
formulae above were deﬁned for a BAF ratio lower than
0.5 (e.g., heterozygous SNPs in allelic imbalance with A be-
ing the ‘‘major’’ allele). To also include the information of
heterozygous SNPs with BAFs higher than 0.5, these SNPs
are converted into values lower than 0.5, ‘‘folding’’ as
shown in Figure 2A (see section III of Appendix A).
Appendix C. Germline Genotype Inference from
Cancer Samples
A reliable germline genotype can be inferred provided that
the bands of heterozygous SNPs are distinct from the bands
of homozygous SNPs. In chromosomal regions that are nor-
mal (regions with a single band of heterozygous SNPs), two
ﬁxed BAF thresholds are used to call the genotypes, corre-912 The American Journal of Human Genetics 82, 903–915, April 20sponding to 0.25 and 0.75. SNPswith BAFs< 0.25 are called
AA, those with BAFs between 0.25 and 0.75 are called AB,
and those with BAFs > 0.75 are called BB.
In chromosomal regions that are in allelic imbalance,
with two-band patterns that are obviously distinct from
the bands of homozygous SNPs (red and green regions de-
ﬁned in Appendix A), two ﬁxed BAF thresholds are used to
call the genotypes corresponding to the 99.9th percentile
of the reference BAF distributions of SNPs AA and BB.
In chromosomal regions that are in allelic imbalance,
but with two-band patterns that are close to the bands of
homozygous SNPs (blue region), SOMATICs models the
distributions of homozygous and heterozygous SNPs.
These model distributions are used to determine the num-
ber of true or false homozygous and heterozygous SNPs as-
sociated with each BAF threshold. A best-discrimination
threshold can thus be identiﬁed.
The ﬁtting of distribution models and the estimation of
numbers of homozygous and heterozygous SNPs are per-
formed differently in the situations of distinct (Figure S4A)
and overlapping (Figure S4B) distributions. To discriminate
between distinct and overlapping distributions, the ﬁrst
step is to assign an a priori genotype (homozygous or het-
erozygous) to the SNPs in this region. A liberal BAF-thresh-
old value is used (95th percentile of the reference homozy-
gous distributions, Figure S4A). The distribution peak of
a priori heterozygous SNPs is then determined as the BAF
distribution class containing the highest number of
SNPs, with a broad class-width deﬁnition (1/3 of the stan-
dard deviation of heterozygous reference SNPs, Figure S4A).
The reference distribution of heterozygous SNPs is centered
on this peak. If the 95th percentile of this reference distribu-
tion centered on this peak is outside of the 95th percentile
of the homozygous reference distribution, the distributions
of homozygous and heterozygous SNPs are considered
distinct (Figure S2A), given that less than 5% of SNPs are ex-
pected to be misclassiﬁed. Otherwise, the distributions are
considered as overlapping (Figure S4B).
In the caseofdistinctdistributions, thedistributionofapri-
ori heterozygous SNPs ismodeledwith the reference distribu-
tion of heterozygous SNPs and the number of heterozygous
SNPs is estimated as the number of a priori heterozygous
SNPs. The distribution of homozygous SNPs is modeled
with the reference distribution of homozygous SNPs, and
the number of homozygous SNPs is estimated by counting
of theSNPswithaBAFbetween0andthe75thﬁrstpercentile
of the reference distribution of AA SNPs (or between the 75th
percentile of the reference distribution of BB SNPs and 1) and
multiplying this number by 4/3 to reach 100%.
In the case of overlapping distributions, it is not possible
to know whether SNPs in the overlapping region are ho-
mozygous or heterozygous. In addition, with BAF values
so close to 0 or 1, the distribution of the SNPs belonging
to the bands of the two-band patterns is tighter than the
reference distribution of heterozygous SNPs. Therefore,
the distribution of heterozygous SNPs is modeled with
the largest 50% of the distribution of a priori heterozygous08
SNPs, e.g., the distribution of SNPs with BAFs higher than
the distribution peak, assuming that the distribution is
symmetric. The number of heterozygous SNPs is estimated
to be twice the number of these SNPs. The distribution of
homozygous SNPs is modeled with the reference homozy-
gous distribution, and the number of homozygous SNPs
is estimated by counting of the SNPs with a BAF between
0 and the 50th percentile of the reference distribution of
AA SNPs (or 1 and the 50th percentile of the reference distri-
bution of BB SNPs) and multiplying this number by 2 to
reach 100%.
The ﬁtted distributions are used to generate cumulative
distribution functions (CDFs) for the homozygous and het-
erozygous SNPs. The CDFs are combined for the estimated
number of heterozygous and homozygous SNPs so that the
numbers of false homozygous, true homozygous, false het-
erozygous, and true heterozygous SNPs can be estimated
for each value of BAF (Figure S4C).
If one BAF threshold yields both true homozygote and
true heterozygote rates greater than 99%, then this thresh-
old is used for the discrimination between homozygous
and heterozygous SNPs. If this criterion cannot be met,
two distinct thresholds are deﬁned, one for calling the ho-
mozygotes and the other for calling the heterozygotes,
both with R 99% true positives. SNPs with intermediate
values are called ‘‘undetermined.’’
Supplemental Data
Supplemental data include four ﬁgures and can be found with this
article online at http://www.ajhg.org/.
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